MDMA has been seen as a promising treatment for PTSD in some studies.

So why did the FDA reject it? I was in the trial that was supposed to determine efficacy.

So how did they know it was efficacious before the trial was even done?

It's Monday, July 22nd, and this is Science Friday.

I'm Cyfry producer Kathleen Davis. Last month, the first psychedelic therapy treatment

came before the Food and Drug Administration

for a vote.

But the FDA Scientific Advisory Panel that saw this

voted overwhelmingly against approving MDMA therapy

for PTSD.

A lot of the hesitation against approval had to do with the methodology

of the clinical trials done by Likos Therapeutics and the Multidisciplinary Association

for Psychodelic Studies or Maps.

Here's guest host Rachel Feltman with more.

Joining me today to talk about this are my guests.

We have Sarah McNamee, a trial participant,

researcher at McGill University, and a licensed psychotherapist

based in Montreal, Quebec, and Eicofreed, a Methodologist, Psychologist, and Associate Professor

at Leiden University in the Netherlands.

Welcome both of you to Science Friday.

I'm so excited to have this conversation.

Thanks for having us on.

...